Pharmaceutical News and Articles

29.4 Percent of U.S. Pharmacies Operating in 2010-2021 Closed by 2021

Almost 30 percent of U.S. pharmacies operating during 2010 to 2021 had closed by 2021, according to a study published in the December issue of Health Affairs. J

American Seniors Struggle to Pay Medical Bills More Than Peers in Other Wealthy Countries

only in Switzerland did seniors spend more on their health care.The survey also found that 8 of Americans on traditional Medicare and 9 of Americans with Medica

20th Century Lead Exposures Took Grim Toll on Americans' Health

can influence our health today, Reuben said. Our job moving forward will be to better understand the role lead has played in the health of our country, and to m

Almost a Third of U.S. Retail Pharmacies Have Closed Since 2010

Illinois, Maine, Mississippi, New York, Pennsylvania, Rhode Island and Vermont. There, more than half of counties experienced a net decline in pharmacies.Black,

E. Coli Outbreak Linked to McDonald's Quarter Pounders Declared Over

a condition that can trigger kidney failure, according to the CDC.More informationThe CDC has more on E. coli.SOURCES U.S. Food and Drug Administration, health

Zepbound Bests Wegovy for Weight Loss in New Trial

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. Given the increa

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm (epinephrine) Sublingual Film

Aquestive Therapeutics, Inc. (NASDAQ AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients lives through innovative sc

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Syros Pharmaceuticals (NASDAQ SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic maligna